Entrez PubMed
Overview
Help
|
FAQ
PubMed Services
Journal
Browser
MeSH
Browser
Single
Citation Matcher
Batch Citation
Matcher
Clinical Queries
Old PubMed
Related Resources
Order Documents
Grateful
Med
Consumer Health
Clinical Alerts
|
|
-
Genotoxicity of 3'-azido-3'-deoxythymidine in the human
lymphoblastoid cell line, TK6: relationships between DNA incorporation, mutant frequency,
and spectrum of deletion mutations in HPRT.
Sussman HE, Olivero OA, Meng Q, Pietras SM, Poirier MC, O'Neill JP, Finette BA,
Bauer MJ, Walker VE
Wadsworth Center, New York State Department of Health, Albany, NY 12201-0509,
USA.
Perinatal treatment with 3'-azido-3'-deoxythymidine (AZT) has been found to
reduce the rate of maternal-infant transmission of HIV; however, AZT is genotoxic in
mammalian cells in vitro and induces tumors in the offspring of mice treated in utero. The
purpose of the present study was to investigate the relationships between incorporation of
AZT into DNA, and the frequency and spectrum of mutations at the HPRT locus of the human
lymphoblastoid cell line, TK6, following in vitro exposures to AZT. Cells were cultured in
medium containing 0 or 300 microM AZT for 1, 3, or 6 day(s) (n = 5/group). The effects of
exposure duration on incorporation of AZT into DNA and HPRT mutant frequency were
determined using an AZT radioimmunoassay and a cell cloning assay, respectively. AZT
accumulated in DNA in a supralinear manner, approaching a plateau at 6 days of treatment
(101.9 +/- 14.7 molecules AZT/10(6) nucleotides). After 3 days of AZT exposure, HPRT
mutant frequency was significantly increased (1.8-fold, p = 0.016) compared to background
(mutant frequency = 3.78 x 10(-6)). Multiplex PCR amplification of genomic DNA was used to
determine the frequency of exon deletions in HPRT mutant clones from untreated cells
versus AZT-treated cells. Molecular analyses of AZT-induced mutations revealed a
significant difference in the frequency of total gene deletions (44/120 vs. 18/114 in
controls, p = 0.004 by the Mann-Whitney U-statistic). In fact, the Chi-square test of
homogeneity demonstrate that the differences between the control and AZT-treatment groups
is attributed mainly to this increase in total gene deletion mutations (p = 0.00001).
These data indicate that the primary mechanism of AZT mutagenicity in human TK6 cells is
through the production of large deletions which occur as a result of AZT incorporation
into DNA and subsequent chain termination. The data imply that perinatal chemoprophylaxis
with AZT may put children of HIV-infected women at potential risk for genetic
damage.
PMID: 10526209, UI: 99456996
|